MRS2500 tetraammonium is a potent, selective and stable antagonist of theP2Y1receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀value of 0.95 nM. Antithrombotic activity^[1][2][3].

MRS2500 tetraammonium inhibits platelet aggregation to 10 μM ADP with an IC₅₀of 0.95 nM in human washed platelets. MRS2500 tetraammonium inhibits platelet aggregation to 10μM ADP with an IC₅₀of 0.49 μM in human PRP^[4].

MRS2500 (2 mg/kg; i.v.) decreases acute systemic thromboembolism through selective inhibition of the P2Y1 receptor^[3].
MRS2500 exhibited strong antithrombotic efficacy in the prevention of arterial thrombosis in the monkey ECAT model^[4]..

629.28

Solid

C₁₃H₃₀IN₉O₈P₂

630103-23-0

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)